Organic Active Ingredients TRIZ Cases

NADH coenzyme supplementation facilitates phenylalanine metabolism through alternative pathways, reducing reliance on expensive low-phenylalanine diets.

A PTEN-45aa oligopeptide suppresses glioma cell growth and penetrates tumor tissues.

Aldehyde derivatized glycosaminoglycans join biologically active molecules through nucleophilic addition to form bioconjugates.

Specific 4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulene compounds improve blood-brain barrier penetration while minimizing off-target side effects.

Modified catecholamine derivatives overcome low oral bioavailability and first-pass metabolism to deliver sustained dopaminergic activity.

Alpha-deuteration extends the half-life of N,N-dimethyltryptamine, eliminating toxic buildup risks in poor metabolizers.

Genetic engineering bacteria secrete diacetylchitobiose deacetylase using a yncM signal peptide.

Identifying loss-of-function mutations in CDKN1A and RB1 genes enables precise selection of cisplatin-based therapies to improve treatment effectiveness.

Replacing synthetic immunostimulators with Aureobasidium sp. beta-glucan resolves the trade-off between reliable immune activation and natural ingredient usage.

Crystallization replaces chromatography to purify aripiprazole lauroxil while sodium bicarbonate substitutes triethylamine in the reaction.

N-substituted arylidenerhodanine compounds stabilize the native tetrameric state of transthyretin to prevent amyloid fibril formation.

Nitrogen atmosphere packaging protects 5-ASA enemas from oxidation, eliminating bowel irritation caused by sulfite stabilizers.

Low-concentration hydrogen peroxide paired with hyaluronic acid resolves the contradiction between disinfection and tissue repair in wound care.

MMP-14 binding proteins inhibit proteolytic activity, reducing tumor growth and metastasis in melanoma and pancreatic cancer.

Controlled crystallization yields stable Marizomib Morphic Form I, resolving the contradiction between manufacturing precision and compound stability.

Dantrolene stabilizes cardiac Ryanodine Receptor 2 to reduce calcium leak and improve defibrillation success.

A single-stranded RNA molecule with specific regions inhibits gene expression through intramolecular folding.

Small molecule compounds inhibit fatty acid synthase activity through selective binding to the thioesterase domain.

Compound 1 targets 5-HT2C receptors to control seizures while avoiding the valvular heart disease risks associated with fenfluramine.

RSC-133 replaces viral vectors to boost reprogramming efficiency and maintain pluripotency without genomic integration risks.

A whey protein isolate and Tween 80 composite emulsifier stabilizes ginsenoside Rg3 and CK nano-emulsions against storage degradation.

A pyridophenanthroline derivative inhibits topoisomerases I and II simultaneously to suppress tumor growth at nanomolar concentrations.

Valine stimulates interferon production to inhibit avian influenza virus proliferation, reducing inflammatory injury and improving survival rates.

Periodic low-dose vitamin B12 supplementation prevents deficiency while minimizing cancer risks associated with continuous high-dose regimens.

An enzymatically resistant polypeptide reduces blood glucose and lipid levels, addressing side effects from conventional diabetes treatments.

Heterocycle compounds inhibit Axl and Mer kinases via specific molecular structures, reducing side effects from off-target activity.

Segmented manufacturing separates excipient compression from probiotic addition, limiting viability loss to 7% compared to 70% in direct methods.

Replacing complex platelet function tests with genetic analysis improves thrombotic risk prediction accuracy and reproducibility.

Direct triplet-triplet energy transfer from a photosensitizer to a BODIPY prodrug enables efficient drug release at 625 nm, avoiding high-power upconversion.

Apyrase depletes extracellular nucleotides alongside P2Y12 inhibition, reducing infarct size while maintaining low bleeding risks.

Pyrrolo[2,3-d]pyrimidinone compounds inhibit cyclin-dependent kinase 2 activity through specific spiro-cyclopropane structural modifications.

Stabilized solid microparticles in a dual-excipient matrix provide sustained therapeutic levels, resolving compliance issues from lengthy oral dosing regimens.

An erodible polymer matrix controls trimetazidine release, reducing peak niacin concentrations that cause flushing while maintaining therapeutic efficacy.

Proteomic blood markers enable patient stratification and treatment monitoring by correlating peripheral protein levels with tissue status.

Glucosylceramide synthase inhibitors target upregulated enzyme activity to suppress proliferation of human papillomavirus-infected cells.

Scorpion venom-derived peptides bind selectively to tumor markers to induce apoptosis, eliminating healthy cell damage from conventional chemotherapy.

Selective laser sintering converts poorly soluble drugs into stable amorphous forms using electromagnetic energy-absorbing excipients.

Bis-triazole triarylpyridines overcome chemoresistance by inducing lysosomal membrane permeabilization to trigger non-apoptotic cell death.

A pharmaceutical composition combining S-Adenosyl-methionine, adaptogenic plant extracts, and vitamins to slow cellular aging.

Peptide compounds inhibit the HCV NS3 protease to overcome limited sustained efficacy of existing interferon therapies.

Replaces chromatography with chiral salt formation and extraction, achieving high optical purity while reducing process complexity.

ACE2 inhibitors mediate viral entry blockage by competing with spike proteins for receptor sites, reducing coronavirus replication.

Purifying benzyl benzoate via antioxidant treatment suppresses fulvestrant sulfone generation during formulation.

Administering alovudine and zidovudine at 1:100 to 1:350 molar ratios mitigates mitochondrial DNA depletion and haematologic toxicity.

Sodium benzoate co-crystals improve bioavailability by selecting co-formers like sorbic acid, reducing development time.

CD99 inhibitors selectively bind CD99 antigens on cancer cells, resolving the contradiction between treatment specificity and intracellular delivery efficiency.

Ruxolitinib blocks the IL-11-Jak/Stat3 pathway driven by stromal Lkb1 loss, reducing tumor burden where COX-2 inhibitors fail.